All News

Investigators highlight the importance of building partnerships between CAR T-cell centers and external hospitals to increase treatment referrals and access to clinical trials for patients with B-cell acute lymphoblastic leukemia.

The FDA sets a Prescription Drug User Fee Act date of December 16, 2023 for pembrolizumab plus chemotherapy for managing metastatic gastric or gastroesophageal junction adenocarcinoma.

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Data from the interim analysis of the phase 3 FLAMES study indicate that senaparib may lengthen progression-free survival in patients with advanced ovarian cancer.

TP-1287 is under investigation as part of a phase 1 study in patients with metastatic or progressive solid tumors, including Ewing sarcoma, that are refractory or intolerant to other established therapies.

There is a clear need for further trials and drug development to mitigate poor outcomes in patients with small cell lung cancer, according to an expert from Yale School of Medicine.

CB-011, which received fast track designation from the FDA, is currently under investigation as a treatment for those with relapsed or refractory multiple myeloma in the phase 1 CaMMouflage trial.

Investigators behind a phase 1 trial investigating MT-0169 in relapsed or refractory multiple myeloma and non-Hodgkin lymphoma will pause enrollment of new patients following prior reports of cardiac adverse effects in 2 patients.

Tavokinogene telseplasmid plus pembrolizumab is reported to be well tolerated in patients with advanced, pre-treated melanoma based on data from the phase 2 KEYNOTE-695 trial.

Primary outcome data from phase 3 confirmatory studies evaluating ibrutinib in mantle cell lymphoma and marginal zone lymphoma are insufficient to support conversion to full FDA approval in these indications.

SynKIR-110, which received fast track designation from the FDA, is currently under investigation as treatment for patients with mesothelioma in the phase 1 STAR-101 trial.

Patients with advanced high-grade epithelial BRCA mutation–negative ovarian cancer appear to benefit from treatment with olaparib and durvalumab plus bevacizumab and chemotherapy.

Farshid Sadeghi, MD, elaborates on improvements in minimally invasive surgery technique and the interdisciplinary cooperation that goes into treating kidney cancer.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.

Data from a phase 1/2 dose escalation study investigating BDC-10001 plus nivolumab in HER2-expressing tumors support the advancement of additional phase 2 trials evaluating the novel antibody conjugate.

Findings from 2 phase 3 trials support the recommendation to approve sodium thiosulfate to reduce the risk of cisplatin-related hearing loss in pediatric patients with solid tumors in Europe.

Factors including ARID1A mutations and tumor mutational burden appear to correlate with progression-free survival and overall survival following immunotherapy for advanced bladder cancer.

Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.

The addition of radiation to chemotherapy did not improve overall survival in patients with advanced endometrial cancer, according to an expert from Northwestern Medicine.

Findings from the phase 3 TRANSFORM study support the Committee for Medicinal Products for Human Use’s recommendation to approve lisocabtagene maraleucel for large B-cell lymphoma.

The safety profile seen in the phase 3 CONTACT-03 trial, assessing cabozantinib and atezolizumab in advanced renal cell carcinoma, is consistent with previous findings.

Progression-free survival and overall survival appear to be worse in patients with metastatic colorectal cancer who have a high- vs low-BRAF allele fraction after treatment with a BRAF inhibitor plus an anti-EGFR agent plus or minus a MEK inhibitor.

The FDA’s decision to lift a partial clinical hold on the phase 1/2 VELA trial follows reports of visual adverse effects in patients with advanced solid tumors in February 2023.

Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical practice.

Ravi Vij, MD, MBA, and Luciano Costa, MD, face off over myeloma data from ASH 2022.

Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.

The FDA has set a Prescription Drug User Fee Act date in the fourth quarter of 2023 for encorafenib plus binimetinib as a treatment for BRAF V600E–mutant metastatic non–small cell lung cancer.

A panel of experts from Moffitt and Mayo discuss newly published data from the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition.